◎ Sugi Atlas

Atlas / Gene / ARHGAP5

ARHGAP5

gene
On this page

Also known as RhoGAP5p190-Bp190BRhoGAP

Summary

ARHGAP5 (Rho GTPase activating protein 5, HGNC:675) is a protein-coding gene on chromosome 14q12, encoding Rho GTPase-activating protein 5 (Q13017). GTPase-activating protein for Rho family members.

Rho GTPase activating protein 5 negatively regulates RHO GTPases, a family which may mediate cytoskeleton changes by stimulating the hydrolysis of bound GTP. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 394 — RefSeq curated summary.

At a glance

  • GWAS associations: 1
  • Clinical variants (ClinVar): 171 total — 1 pathogenic, 1 likely-pathogenic
  • Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 5 cancer types
  • MANE Select transcript: NM_001030055

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:675
Approved symbolARHGAP5
NameRho GTPase activating protein 5
Location14q12
Locus typegene with protein product
StatusApproved
AliasesRhoGAP5, p190-B, p190BRhoGAP
Ensembl geneENSG00000100852
Ensembl biotypeprotein_coding
OMIM602680
Entrez394

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 13 protein_coding, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000216743, ENST00000345122, ENST00000396582, ENST00000433497, ENST00000539826, ENST00000554090, ENST00000555814, ENST00000556191, ENST00000556611, ENST00000557643, ENST00000865796, ENST00000940433, ENST00000940434, ENST00000940435, ENST00000955200

RefSeq mRNA: 2 — MANE Select: NM_001030055 NM_001030055, NM_001173

CCDS: CCDS32062, CCDS45095

Canonical transcript exons

ENST00000345122 — 7 exons

ExonStartEnd
ENSE000014116903207730432077435
ENSE000036897983215242332152528
ENSE000038922413215462132159728
ENSE000038922593209050232094386
ENSE000038927373214626332146340
ENSE000038932913214990232150033
ENSE000038945873211714032117287

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 98.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.3709 / max 358.8404, expressed in 1636 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter IDTPM avgSamples expressed
1391115.56481478
1391134.34151312
1391090.6288227
1391120.5218249
1391100.200384
1391150.113745

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
calcaneal tendonUBERON:000370198.93gold quality
ventricular zoneUBERON:000305397.68gold quality
endothelial cellCL:000011596.98gold quality
choroid plexus epitheliumUBERON:000391196.80gold quality
colonic epitheliumUBERON:000039796.38gold quality
Brodmann (1909) area 23UBERON:001355495.94gold quality
corpus callosumUBERON:000233695.92gold quality
pigmented layer of retinaUBERON:000178295.72gold quality
adrenal tissueUBERON:001830395.29gold quality
buccal mucosa cellCL:000233695.24gold quality
corpus epididymisUBERON:000435995.07gold quality
esophagus squamous epitheliumUBERON:000692094.68gold quality
caput epididymisUBERON:000435894.66gold quality
entorhinal cortexUBERON:000272894.26gold quality
ganglionic eminenceUBERON:000402394.17gold quality
mucosa of paranasal sinusUBERON:000503094.02gold quality
islet of LangerhansUBERON:000000693.96gold quality
heart right ventricleUBERON:000208093.90gold quality
jejunal mucosaUBERON:000039993.77gold quality
cauda epididymisUBERON:000436093.71gold quality
primary visual cortexUBERON:000243693.44gold quality
postcentral gyrusUBERON:000258193.28gold quality
substantia nigra pars reticulataUBERON:000196693.13gold quality
oral cavityUBERON:000016793.10gold quality
cranial nerve IIUBERON:000094193.00gold quality
myocardiumUBERON:000234992.81gold quality
superior frontal gyrusUBERON:000266192.72gold quality
parietal lobeUBERON:000187292.62gold quality
subthalamic nucleusUBERON:000190692.30gold quality
occipital lobeUBERON:000202192.19gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-ANND-3yes10.13
E-GEOD-135922yes8.15
E-GEOD-124858no829.35
E-MTAB-5061no3.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

269 targeting ARHGAP5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-3163100.0077.238605
HSA-MIR-1277-5P100.0073.955056
HSA-MIR-3613-3P100.0076.367965
HSA-MIR-5692B100.0071.322622
HSA-MIR-5692C100.0071.322622
HSA-MIR-3924100.0072.092394
HSA-LET-7A-3P100.0074.033932
HSA-LET-7B-3P100.0074.083913
HSA-LET-7F-1-3P100.0074.023928
HSA-MIR-98-3P100.0074.083907
HSA-MIR-3925-3P100.0069.951237
HSA-MIR-340-5P100.0072.504437
HSA-MIR-3646100.0073.565283
HSA-MIR-656-3P100.0072.152788
HSA-MIR-6740-5P100.0065.64932
HSA-MIR-3064-3P100.0070.091254
HSA-MIR-548C-3P99.9974.017587
HSA-MIR-186-5P99.9970.833707
HSA-MIR-513B-5P99.9969.962150
HSA-MIR-428299.9975.366408
HSA-MIR-371B-5P99.9975.344759
HSA-MIR-366299.9973.825684
HSA-MIR-4789-3P99.9970.752484
HSA-MIR-511-3P99.9968.851467
HSA-MIR-477599.9875.006394
HSA-MIR-373-5P99.9875.364753
HSA-MIR-616-5P99.9875.584775
HSA-MIR-103A-3P99.9869.141595
HSA-MIR-10799.9869.141595
HSA-MIR-3692-3P99.9870.272139

Literature-anchored findings (GeneRIF, showing 15)

  • A cell cycle-regulated reduction in endogenous p190 levels is linked to completion of cytokinesis and generation of viable cell progeny. (PMID:14610059)
  • precise control of p190-B Rho GTPase-activating protein activity is critical for normal branching morphogenesis during mammary gland development (PMID:16469769)
  • ARHGAP5 (the gene encoding p190-B RhoGAP) is a probable target for the amplification at 14q12, and p190-B RhoGAP promotes cells spreading and migration by negatively regulating RhoA activity in Huh-7 hepatocellular carcinoma cells (PMID:18996642)
  • Results link Cdk5 to Rho-ROCK signaling via Src and p190RhoGAP and implicate Cdk5 in the regulation of cell contraction, attachment, and migration. (PMID:19822667)
  • The expression level of miR-486-5p was inversely correlated with that of ARHGAP5. (PMID:23474761)
  • RhoA is down-regulated at cell-cell contacts via p190RhoGAP-B in response to tensional homeostasis. (PMID:23552690)
  • Data indicate a role for p120-catenin (amino acids 820-843) domain in the p120-catenin.p190RhoGAP signaling complex assembly and membrane targeting. (PMID:23653363)
  • Ectopic expression of p190B suppressed the miR-494-induced EGFR upregulation. (PMID:24316134)
  • This newly identified miR-744/ARHGAP5 pathway provides further insight into the progression and metastasis of NPC and indicates potential novel therapeutic targets for NPC. (PMID:25961434)
  • only collagen-IV elicits the formation of proteolytically active podosomes through a mechanism involving increased Src phosphorylation, p190RhoGAP-B (also known as ARHGAP5) relocalisation and MT1-MMP (also known as MMP14) cell surface exposure at podosome sites. (PMID:27231093)
  • Brazilian Amerindian ancestry compared to Asian, European, and African Genomes.SNPs within or proximal to CIITA (rs6498115), SMC6 (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch. SNPs in ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) in the Asian comparison. (PMID:28100790)
  • These results indicate that SIRT1 suppresses migration and invasion of gastric cancer by downregulating ARHGAP5 through an interaction with c-JUN, and these phenomena represent a novel mechanism of the antitumor action of SIRT1. (PMID:30250020)
  • Investigation of the role and mechanism of ARHGAP5-mediated colorectal cancer metastasis. (PMID:32483433)
  • The p190 RhoGAPs, ARHGAP35, and ARHGAP5 are implicated in GnRH neuronal development: Evidence from patients with idiopathic hypogonadotropic hypogonadism, zebrafish, and in vitro GAP activity assay. (PMID:36178483)
  • Circular RNA ARHGAP5 inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with AUF1. (PMID:36632741)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_rerioarhgap5ENSDARG00000061294
mus_musculusArhgap5ENSMUSG00000035133
rattus_norvegicusArhgap5ENSRNOG00000004696

Paralogs (2): TCERG1 (ENSG00000113649), TCERG1L (ENSG00000176769)

Protein

Protein identifiers

Rho GTPase-activating protein 5 — Q13017 (reviewed: Q13017)

Alternative names: Rho-type GTPase-activating protein 5, p190-B

All UniProt accessions (5): Q13017, G3V360, G3V444, G3V5I7, H0YK04

UniProt curated annotations — full annotation on UniProt →

Function. GTPase-activating protein for Rho family members.

Subunit / interactions. May interact with RASA1/p120GAP.

Subcellular location. Cytoplasm. Cell membrane.

Tissue specificity. Detected in skin fibroblasts (at protein level).

Domain organisation. The pG1 pseudoGTPase domain does not bind GTP.

Isoforms (4)

UniProt IDNamesCanonical?
Q13017-11yes
Q13017-22
Q13017-33
Q13017-44

RefSeq proteins (2): NP_001025226, NP_001164 (=MANE)

Domains & families (InterPro)

IDNameType
IPR000198RhoGAP_domDomain
IPR002713FF_domainDomain
IPR008936Rho_GTPase_activation_protHomologous_superfamily
IPR027417P-loop_NTPaseHomologous_superfamily
IPR032835RhoGAP-FF1Domain
IPR036517FF_domain_sfHomologous_superfamily
IPR039006RhoGAP_pG2Domain
IPR039007pG1Domain
IPR045786RhoGAP_pG1_pG2Domain
IPR051978Rho-GAP_domainFamily
IPR057284FF_RHG35_4thDomain

Pfam: PF00620, PF01846, PF16512, PF19518, PF23083

UniProt features (65 total): helix 16, modified residue 11, strand 9, domain 7, region of interest 5, sequence conflict 5, splice variant 4, turn 3, compositionally biased region 2, chain 1, site 1, sequence variant 1

Structure

Experimental structures (PDB)

3 structures.

PDBMethodResolution (Å)
5U4VX-RAY DIFFRACTION2.6
2EE4SOLUTION NMR
2EE5SOLUTION NMR

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q13017-F173.370.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 1297 (arginine finger; crucial for gtp hydrolysis by stabilizing the transition state)

Post-translational modifications (11): 550, 590, 765, 951, 968, 1115, 1173, 1176, 1195, 1202, 1218

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

IDPathway
R-HSA-8980692RHOA GTPase cycle
R-HSA-9013026RHOB GTPase cycle
R-HSA-9013106RHOC GTPase cycle
R-HSA-9013148CDC42 GTPase cycle
R-HSA-9013149RAC1 GTPase cycle
R-HSA-9013405RHOD GTPase cycle
R-HSA-9013406RHOQ GTPase cycle
R-HSA-9013408RHOG GTPase cycle
R-HSA-9013409RHOJ GTPase cycle
R-HSA-9013423RAC3 GTPase cycle
R-HSA-9035034RHOF GTPase cycle
R-HSA-9696264RND3 GTPase cycle
R-HSA-9696270RND2 GTPase cycle
R-HSA-9696273RND1 GTPase cycle

MSigDB gene sets: 363 (showing top): BIOCARTA_RHO_PATHWAY, CREL_01, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, CCAWYNNGAAR_UNKNOWN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, TATTATA_MIR374, CTATGCA_MIR153, GGGTGGRR_PAX4_03, GTACAGG_MIR486, chr14q12, NFKB_C, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE

GO Biological Process (10): positive regulation of mesenchymal cell proliferation (GO:0002053), cell adhesion (GO:0007155), Rho protein signal transduction (GO:0007266), regulation of cell size (GO:0008361), epithelial cell migration (GO:0010631), positive regulation of epithelial cell migration (GO:0010634), mammary gland development (GO:0030879), regulation of small GTPase mediated signal transduction (GO:0051056), signal transduction (GO:0007165), cell migration (GO:0016477)

GO Molecular Function (4): GTPase activity (GO:0003924), GTPase activator activity (GO:0005096), SH2 domain binding (GO:0042169), protein binding (GO:0005515)

GO Cellular Component (5): cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

CategoryPathways
RHO GTPase cycle14

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure3
cellular process2
small GTPase-mediated signal transduction2
cytoplasm2
positive regulation of cell population proliferation1
mesenchymal cell proliferation1
regulation of mesenchymal cell proliferation1
regulation of cellular component size1
ameboidal-type cell migration1
epithelium migration1
epithelial cell migration1
regulation of epithelial cell migration1
positive regulation of cell migration1
gland development1
regulation of intracellular signal transduction1
cell communication1
signaling1
regulation of cellular process1
cellular response to stimulus1
cell motility1
ribonucleoside triphosphate phosphatase activity1
GTPase activity1
enzyme activator activity1
GTPase regulator activity1
protein domain specific binding1
binding1
intracellular anatomical structure1
endomembrane system1
intracellular membrane-bounded organelle1
membrane1
cell periphery1

Protein interactions and networks

STRING

992 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
ARHGAP5CTNND2Q9UQB3787
ARHGAP5AKT1P31749779
ARHGAP5RHOAP06749758
ARHGAP5CTNND1O60716733
ARHGAP5RND3P52199699
ARHGAP5SRCP12931695
ARHGAP5METTL3Q86U44623
ARHGAP5CDH17Q12864579
ARHGAP5KAZNQ674X7569
ARHGAP5CDC42P21181552
ARHGAP5ITGA5P08648515
ARHGAP5ITGB1P05556423
ARHGAP5RALGAPA1Q6GYQ0421
ARHGAP5FAM91A1Q658Y4417
ARHGAP5HAUS8Q9BT25408

IntAct

13 interactions, top by confidence:

ABTypeScore
PLK1SPAG9psi-mi:“MI:0914”(association)0.790
ARHGAP5SMURF2psi-mi:“MI:0915”(physical association)0.550
ARHGAP5H1-1psi-mi:“MI:0915”(physical association)0.400
ARHGAP5Rnd3psi-mi:“MI:0915”(physical association)0.400
Rnd3ARHGAP5psi-mi:“MI:0915”(physical association)0.400
ARHGAP5psi-mi:“MI:0915”(physical association)0.370
KAZNINPPL1psi-mi:“MI:0914”(association)0.350
SMURF2NEDD4psi-mi:“MI:0914”(association)0.350
RETREG3SLC27A2psi-mi:“MI:0914”(association)0.350
CDH1ESYT2psi-mi:“MI:2364”(proximity)0.270
PTPRUARHGAP5psi-mi:“MI:2364”(proximity)0.270
HSPA13ARHGAP5psi-mi:“MI:0915”(physical association)0.000

BioGRID (86): ARHGAP5 (Affinity Capture-RNA), ARHGAP5 (Proximity Label-MS), ARHGAP5 (Proximity Label-MS), ARHGAP5 (Affinity Capture-MS), ARHGAP5 (Affinity Capture-MS), ARHGAP5 (Affinity Capture-MS), RND3 (Two-hybrid), ARHGAP5 (Affinity Capture-MS), RND1 (Two-hybrid), RND2 (Two-hybrid), ARHGAP5 (Affinity Capture-Western), ARHGAP5 (Affinity Capture-Western), ARHGAP5 (Affinity Capture-Western), ARHGAP5 (Affinity Capture-Western), ARHGAP5 (Reconstituted Complex)

ESM2 similar proteins: A0A0G2K344, A0A3Q1N1R0, E1BKH1, G3GTP0, G5EF51, O13728, O70481, P06814, P16259, P16885, P20807, P24135, P32871, P34529, P35875, P42336, P42337, P43368, P49917, P51186, P97393, Q09879, Q11208, Q13017, Q32TF8, Q32TG3, Q4V8Q1, Q5JST6, Q5JVL4, Q5R6L3, Q64691, Q6GL75, Q6GQ76, Q6J756, Q6NU25, Q758X6, Q803R5, Q8BTF7, Q8BTI9, Q8CIH5

Diamond homologs: A0A0G2JTR4, A1A4S6, A2AB59, A2RUV4, A4IF90, A4II46, A6QNS3, A6X8Z5, A7KAX9, A7YY57, A8WRJ2, D3ZFJ3, E7EZG2, E7F3F0, F1LXF1, O14559, O94466, P11274, P15882, P30337, P34288, P38339, P46941, P52757, P55194, P81128, P97393, Q03070, Q08DP6, Q10164, Q12979, Q13017, Q15311, Q17QN0, Q20498, Q2M1Z3, Q3TBD2, Q3UIA2, Q52LW3, Q53QZ3

SIGNOR signaling

4 interactions.

AEffectBMechanism
PTK6up-regulatesARHGAP5phosphorylation
ARHGAP5“down-regulates activity”RHOA“gtpase-activating protein”
SRC“up-regulates activity”ARHGAP5phosphorylation

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 5 cancer types — BLCA, PAAD, PCM, PLMESO, WDTC.

Clinical variants and AI predictions

ClinVar

171 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic1
Likely pathogenic1
Uncertain significance156
Likely benign2
Benign6

Top pathogenic / likely-pathogenic (2)

Variant IDHGVSClassification
1696854NM_001030055.2(ARHGAP5):c.1421T>C (p.Val474Ala)Pathogenic
1679912NM_001030055.2(ARHGAP5):c.2366dup (p.Phe790fs)Likely pathogenic

SpliceAI

1125 predictions. Top by Δscore:

VariantEffectΔscore
14:32090497:TATA:Tacceptor_loss1.0000
14:32090499:TAG:Tacceptor_loss1.0000
14:32090500:AGGA:Aacceptor_loss1.0000
14:32090501:G:GAacceptor_loss1.0000
14:32117138:A:AGacceptor_gain1.0000
14:32117139:G:GGacceptor_gain1.0000
14:32117139:GCA:Gacceptor_gain1.0000
14:32146259:TTAG:Tacceptor_loss1.0000
14:32146261:A:AGacceptor_gain1.0000
14:32146261:A:Gacceptor_loss1.0000
14:32146261:AG:Aacceptor_gain1.0000
14:32146261:AGG:Aacceptor_gain1.0000
14:32146262:G:Aacceptor_loss1.0000
14:32146262:G:GCacceptor_gain1.0000
14:32146262:GG:Gacceptor_gain1.0000
14:32146262:GGG:Gacceptor_gain1.0000
14:32146262:GGGT:Gacceptor_gain1.0000
14:32146262:GGGTT:Gacceptor_gain1.0000
14:32146341:G:GAdonor_loss1.0000
14:32146341:G:GGdonor_gain1.0000
14:32146342:T:Gdonor_loss1.0000
14:32149897:TGTA:Tacceptor_loss1.0000
14:32149899:TA:Tacceptor_loss1.0000
14:32149900:A:ACacceptor_loss1.0000
14:32149900:A:AGacceptor_gain1.0000
14:32149901:G:GAacceptor_gain1.0000
14:32149901:GAT:Gacceptor_gain1.0000
14:32149901:GATC:Gacceptor_gain1.0000
14:32149901:GATCA:Gacceptor_gain1.0000
14:32150029:AGCAA:Adonor_gain1.0000

AlphaMissense

10024 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
14:32090724:G:AG19R1.000
14:32090724:G:CG19R1.000
14:32090725:G:AG19E1.000
14:32090766:G:AG33R1.000
14:32090766:G:CG33R1.000
14:32090767:G:AG33E1.000
14:32090769:A:CK34Q1.000
14:32090773:C:TS35F1.000
14:32090839:T:CL57P1.000
14:32090841:A:CS58R1.000
14:32090842:G:TS58I1.000
14:32090843:C:AS58R1.000
14:32090843:C:GS58R1.000
14:32090850:G:CD61H1.000
14:32090851:A:CD61A1.000
14:32090851:A:GD61G1.000
14:32090851:A:TD61V1.000
14:32090853:T:CF62L1.000
14:32090854:T:CF62S1.000
14:32090855:T:AF62L1.000
14:32090855:T:GF62L1.000
14:32090873:C:AN68K1.000
14:32090873:C:GN68K1.000
14:32090892:T:AW75R1.000
14:32090892:T:CW75R1.000
14:32090961:T:CF98L1.000
14:32090962:T:CF98S1.000
14:32090963:C:AF98L1.000
14:32090963:C:GF98L1.000
14:32090971:A:TD101V1.000

dbSNP variants (sampled 300 via entrez): RS1000009796 (14:32151419 T>C), RS1000041778 (14:32108919 A>C,G), RS1000110961 (14:32088092 T>C), RS1000132040 (14:32128494 C>T), RS1000154511 (14:32160075 G>A,T), RS1000165525 (14:32145415 C>G), RS1000277263 (14:32102037 C>T), RS1000302700 (14:32109157 G>C), RS1000360981 (14:32144210 G>A), RS1000366295 (14:32074026 T>G), RS1000375812 (14:32112646 G>A,T), RS1000402676 (14:32095735 T>G), RS1000428669 (14:32145668 T>G), RS1000465149 (14:32106973 C>T), RS1000508917 (14:32156192 G>A)

Disease associations

OMIM: gene MIM:602680 | disease phenotypes: MIM:212720

GenCC curated gene-disease

Mondo (1): Martsolf syndrome 1 (MONDO:8000008)

Orphanet (1): Cataract-intellectual disability-hypogonadism syndrome (Orphanet:1387)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

StudyTraitp-value
GCST005212_24Asthma4.000000e-06

MeSH disease descriptors (1)

DescriptorNameTree numbers
C536028Martsolf syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Valproic Acidincreases expression, decreases expression, affects expression, affects cotreatment9
methylmercuric chloridedecreases expression3
trichostatin Adecreases expression, affects cotreatment3
sodium arsenitedecreases expression, increases expression3
Cadmium Chlorideincreases expression, decreases expression, increases abundance3
entinostatdecreases expression, affects cotreatment2
Panobinostataffects cotreatment, decreases expression2
Cisplatindecreases expression, increases expression2
Lactic Acidincreases expression2
aristolochic acid Idecreases expression1
FR900359affects phosphorylation1
dicrotophosdecreases expression1
2,4,6-tribromophenoldecreases expression1
triphenyl phosphateaffects expression1
decabromobiphenyl etherdecreases expression1
tetrabromobisphenol Adecreases expression1
4-hydroxy-2-nonenaldecreases expression1
nickel sulfatedecreases expression1
coumarinaffects phosphorylation1
S-(1,2-dichlorovinyl)cysteineaffects response to substance, increases expression1
di-n-butylphosphoric acidaffects expression1
perfluorooctane sulfonic aciddecreases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, decreases expression1
14-deoxy-11,12-didehydroandrographolidedecreases expression1
2,2’,4,4’-tetrabromodiphenyl etherdecreases expression1
dorsomorphinaffects cotreatment, decreases expression1
pentabrominated diphenyl ether 100decreases expression1
hexabrominated diphenyl ether 153decreases expression1
jinfukangdecreases expression1
Irinotecandecreases expression, increases expression1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

  • Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): Martsolf syndrome 1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 75

This page pulls from 75 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot